Accepted Manuscript



Current progress toward a better understanding of drug disposition within the lungs: summary proceedings of the 1st Workshop on Drug Transporters in the Lungs

Carsten Ehrhardt, Per Bäckman, William Couet, Chris Edwards, Ben Forbes, Markus Fridén, Mark Gumbleton, Ken-ichi Hosoya, Yukio Kato, Takeo Nakanishi, Mikihisa Takano, Tetsuya Terasaki, Ryoko Yumoto

PII: S0022-3549(17)30243-5

DOI: 10.1016/j.xphs.2017.04.011

Reference: XPHS 733

To appear in: Journal of Pharmaceutical Sciences

Received Date: 25 February 2017

Revised Date: 7 April 2017

Accepted Date: 7 April 2017

Please cite this article as: Ehrhardt C, Bäckman P, Couet W, Edwards C, Forbes B, Fridén M, Gumbleton M, Hosoya Ki, Kato Y, Nakanishi T, Takano M, Terasaki T, Yumoto R, Current progress

toward a better understanding of drug disposition within the lungs: summary proceedings of the 1st Workshop on Drug Transporters in the Lungs, *Journal of Pharmaceutical Sciences* (2017), doi: 10.1016/j.xphs.2017.04.011.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

ACCEPTED MANUSCRIPT

Current progress toward a better understanding of drug disposition within the lungs: summary proceedings of the 1st Workshop on Drug Transporters in the Lungs

Carsten Ehrhardt^{1,*}, Per Bäckman², William Couet³, Chris Edwards⁴, Ben Forbes⁵, Markus Fridén⁶, Mark Gumbleton⁷, Ken-ichi Hosoya⁸, Yukio Kato⁹, Takeo Nakanishi¹⁰, Mikihisa Takano¹¹, Tetsuya Terasaki¹², Ryoko Yumoto¹¹

¹School of Pharmacy and Pharmaceutical Sciences, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland

²Mylan Global Respiratory Group, Sandwich, UK

³Inserm U1070, Université de Poitiers, UFR Médecine-Pharmacie, CHU Poitiers, Poitiers, France

⁴Refractory Respiratory Inflammation DPU, GlaxoSmithKline Medicines Research Centre, Stevenage, Hertfordshire, United Kingdom

⁵Institute of Pharmaceutical Science, King's College London, London, United Kingdom

⁶Translational PKPD Group, Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden; Respiratory, Inflammation and Autoimmunity Innovative Medicines, AstraZeneca R&D Gothenburg, Mölndal, Sweden.

⁷Experimental Therapeutics, School of Pharmacy and Pharmaceutical Sciences, Cardiff University Cardiff, Wales, United Kingdom

⁸Department of Pharmaceutics, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Japan

⁹Department of Molecular Pharmacotherapeutics, Faculty of Pharmaceutical Sciences, Kanazawa University, Kanazawa, Japan

¹⁰Department of Membrane Transport and Biopharmaceutics, Faculty of Pharmaceutical Sciences, Kanazawa University, Kanazawa, Japan

¹¹Graduate School of Biomedical & Health Sciences, Hiroshima University, Hiroshima, Japan

¹²Graduate School of Pharmaceutical Sciences, Tohoku University, Miyagi, Japan

Corresponding author

Dr. Carsten Ehrhardt, School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, Panoz Institute, Dublin 2, Ireland, tel.: +353-1-896-2441, email: <u>ehrhardc@tcd.ie</u>

Download English Version:

https://daneshyari.com/en/article/8513859

Download Persian Version:

https://daneshyari.com/article/8513859

Daneshyari.com